The study, published Jan. 24 in Neuro-Oncology, examined data from 101 asymptomatic patients diagnosed with stage 4 breast cancer, including triple-negative, HER2-positive and hormone receptor-positive/HER2-negative breast cancer. Patients underwent an initial MRI scan to check for brain metastasis, then a second MRI six months later if the initial scan showed no signs of cancer spread.
Here are four things to know:
1. In the initial MRI, 14% of patients had brain metastasis.
2. Brain metastasis in the first scan was most common in patients with triple-negative breast cancer at 18%, followed by patients with HER2-positive breast cancer at 15% and hormone receptor-positive/HER2-negative breast cancer at 10%.
3. Following the six-month MRI, the rates of brain metastasis increased to 25% for triple-negative, 24% for HER2+ and 23% for HR+/HER2- patients.
4. Currently, screening for asymptomatic stage 4 breast cancer with brain MRIs is not recommended by the National Comprehensive Cancer Network Guidelines.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
